Skip to main content
GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD. logo

GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 603983 ISIN · CNE100003M51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-05-20 AGM Information
Country CN China
Listing Shanghai Stock Exchange 603983

About GUANGDONG MARUBI BIOTECHNOLOGY CO., LTD.

https://www.marubi.cn/

Guangdong Marubi Biotechnology Co., Ltd. focuses on the research, development, and production of specialized skincare and cosmetic products. The organization is primarily recognized for its technological advancements in eye care and anti-aging formulations. Its core operations involve the synthesis of bioactive ingredients and the formulation of high-performance topical treatments, including serums, creams, and masks. Through its flagship brand and various subsidiary labels, the company addresses diverse consumer needs ranging from premium skincare to professional-grade makeup. The business integrates scientific research with modern manufacturing processes, utilizing a distribution network that spans physical retail outlets and digital commerce platforms. Key focus areas include skin physiology, ingredient efficacy, and the application of biotechnology to enhance dermatological health.

Recent filings

Filing Released Lang Actions
广东丸美生物技术股份有限公司2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document contains the 2025 Annual Shareholders’ Meeting materials for Guangdong Marubi Biotechnology Co., Ltd., including meeting notices, agenda, board reports, proposals (e.g., profit distribution plan, director remuneration), and procedural guidelines. It is clearly the presentation and materials for the Annual General Meeting rather than the Annual Report itself or a regulatory announcement. This matches the AGM Information category.
2026-05-20 Chinese
广东丸美生物技术股份有限公司2025年度环境、社会与公司治理（ESG）报告（英文版）
Environmental & Social Information Classification · 92% confidence The document is a full-length 2025 Environmental, Social and Governance Report for Guangdong Marubi Biotechnology Co., Ltd., with detailed sections on ESG governance, environmental protection, social responsibility, governance structures, performance indicators, and appendices. It is not merely an announcement or a financial report but a comprehensive ESG disclosure, matching the definition of Environmental & Social Information.
2026-05-20 English
广东丸美生物技术股份有限公司关于第五届董事会第十五次会议决议的公告
Regulatory Filings Classification · 75% confidence The document is titled “第五届董事会第十五次会议决议公告,” detailing the board of directors’ meeting resolutions (auditor reappointment and use of idle raised funds) with vote results. It is not an earnings release, annual or interim report, audit report, proxy statement, dividend notice, or management/board change announcement. It does not contain substantive financial statements but rather board meeting resolutions. As there is no dedicated category for board resolutions, it falls under general regulatory announcements. Thus, it should be classified as a Regulatory Filing (RNS).
2026-05-13 Chinese
中信证券股份有限公司关于广东丸美生物技术股份有限公司使用部分闲置募集资金临时补充流动资金的核查意见
Regulatory Filings Classification · 82% confidence The document is a sponsor’s verification opinion (“核查意见”) by CITIC Securities on the use of IPO raised proceeds to temporarily supplement working capital. It is not an annual or interim financial report, earnings release, or dividend notice. Rather, it is a regulatory compliance document required under Chinese securities rules. It does not contain audited financial statements or substantive financial data characteristic of an Annual Report (10-K), Interim Report (IR), Audit Report (AR), or Capital/Financing update (CAP). Therefore the appropriate category is the fallback “Regulatory Filings” (RNS).
2026-05-13 Chinese
广东丸美生物技术股份有限公司关于续聘2026年度会计师事务所的公告
Regulatory Filings Classification · 85% confidence The document is an official corporate “公告” regarding the board’s proposal and approval to re-appoint the company’s external auditor for fiscal 2026. It does not contain financial statements or actual audit findings (so it’s not an AR or 10-K/IR), nor is it a change in management or director (so not MANG), nor is it an AGM materials or voting result (AGM-R/DVA). It is a regulatory announcement about auditor appointment, which falls under the general Regulatory Filings (RNS) fallback category.
2026-05-13 Chinese
广东丸美生物技术股份有限公司关于2025年年度股东会增加临时提案的公告
Proxy Solicitation & Information Statement Classification · 90% confidence The document is an official announcement by the company’s board concerning the 2025 Annual General Meeting, specifically adding a temporary proposal, providing meeting details (date, record date, proposals), and including a proxy form. It is sent to shareholders to inform them and solicit votes on the agenda items. It is not the voting result nor a financial report. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-13 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.